Navigation Links
Niiki Pharma Reports on Synergistic Activity of Novel Anti-Cancer Agent NKP-1339 with Other Anti-Cancer Agents
Date:11/15/2011

HOBOKEN, N.J. and PHILADELPHIA, Nov. 15, 2011 /PRNewswire/ -- Niiki Pharma Inc. presented the results of preclinical combination studies of its lead product, NKP-1339, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held in San Francisco, CA, November 12-16, 2011.

The data were presented as a poster, titled "NKP-1339 synergistic activity in both in vitro and in vivo preclinical models highlights the therapeutic opportunity for NKP-1339 combination trials with a broad range of anti-tumor agents."

Data summary:

  • In vitro combination studies were performed in breast, colon, lung, gastric, prostate, pancreatic and liver tumor cell lines.  NKP-1339 was tested in combination with cisplatin, oxaliplatin, 5-FU, docetaxel, doxorubicin, gemcitabine, erlotinib or sorafenib as appropriate for each tumor cell type. Synergistic cytotoxicity was seen with all combinations tested.
  • In vivo gastric carcinoma xenograft model was tested with NKP-1339 in combination with cisplatin. The combination showed significant (P<0.05) tumor growth delay and extended survival when compared to the single agent activity for either compound.

  • The broad synergism of NKP-1339 across the tested anti-neoplastic agents is consistent with its proposed mechanism of action through inhibition of the GRP78 pathway.

    "The synergy we have demonstrated in both in vitro and in vivo settings suggests that NKP-1339 will be effective in combination with these anti-cancer agents in the clinical setting. The favorable efficacy and safety profile observed to date in our ongoing single agent NKP-1339 Phase I trial warrants its investigation in combination studies for our next round of clinical trials," noted Angela Ogden MD, Chief Medical Officer at Niiki Pharma.

    About NKP-1339NKP-1339 is a first-in-class small molecule anti-cancer compound. NKP-1339 down-regulates the GRP78 pathway, a key regulator of mis-folded protein processing and a tumor survival factor. Up-regulation of GRP78 is associated with intrinsic and chemotherapy-induced resistance in many tumor types. In preclinical studies, single agent NKP-1339 has demonstrated activity against multiple tumor types, including those resistant to other anti-cancer agents.

    NKP-1339 was discovered by Professor Bernhard K. Keppler, Dean of the Faculty of Chemistry at University of Vienna, Austria and President of Austrian Association of University Professors.

    About Niiki Pharma Inc.Niiki Pharma is a development focused oncology company specializing in first-in-class cancer treatments directed at novel cellular targets and related companion diagnostics.LinksNiiki Pharma Inc.

    www.niikipharma.comProfessor Bernhard K. Keppler, University of Vienna

    http://anorg-chemie.univie.ac.at
    '/>"/>

    SOURCE Niiki Pharma Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Niiki Pharma Announces Positive Interim Data from Ongoing Clinical Trial of Novel Anti-Cancer Agent NKP-1339
    2. Novel First-in-Class Anti-Cancer Agent in Development by Niiki Pharma Shows Promising Phase I Results
    3. Radient Pharmaceuticals Announces FY 2011 Third Quarter Results
    4. CureFAKtor Pharmaceuticals Demonstrates Novel Focal Adhesion Kinase (FAK) Inhibitor C4 Analogs Inhibited Pancreatic Cancer Tumor Growth as Single Agents
    5. Qualitest Pharmaceuticals Receives FDA Approval for Acetaminophen and Codeine Phosphate Oral Solution USP, 120mg/12mg per 5mL
    6. Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting
    7. Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2011 Results
    8. E7: The Outlook for Pharmaceuticals to 2012
    9. The Outlook for Pharmaceuticals in Central Asia
    10. The Outlook for Pharmaceuticals in Northern Europe
    11. Emerging Pharmaceutical Markets Globally
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/23/2017)... 23, 2017  Additive Orthopaedics, LLC., an early ... has kicked off a multi-centered clinical study to ... segments. According to Brian McLaughlin ... lattice structures have already shown tremendous post-operative success ... allograft wedges from which we have seen evidence ...
    (Date:3/23/2017)... 23, 2017 Newborns are highly vulnerable ... vaccines because their young immune systems typically mount ... Hospital report achieving strong vaccine responses in newborn ... before human trials — by adding compounds known ... two simultaneous papers, they also describe improved adjuvant ...
    (Date:3/23/2017)...  A new genetic test has been discovered ... who carry HLA-B*15:02 and who are ... deadly side effect of certain medications used to ... HLA-B*15:02 is strongly associated with life-threatening severe ... toxic epidermal necrolysis in patients treated with carbamazepine ...
    Breaking Medicine Technology:
    (Date:3/23/2017)... ... ... 150+ Hospital and Health System Executive Speakers including: , , Chief ... the United States of America: George W. Bush , Boxing Legend, Successful Entrepreneur ... Leonard , JD, Chairperson, McGuireWoods LLP: Amber McGraw Walsh , Senior ...
    (Date:3/23/2017)... Grants Pass, OR (PRWEB) , ... March 23, 2017 , ... ... Power of Water, Global Climate Change and Your Health on VoiceAmerica, recently talked on ... 22nd, but she also used the occasion to remind listeners of an important distinction. ...
    (Date:3/23/2017)... ... March 23, 2017 , ... Natural ... all aspects of people’s health and nutrition, announced its product Leyzene is now ... Natural Subsistence develops nutritional supplements that help people improve all aspects of their ...
    (Date:3/23/2017)... ... ... Inflow IQ & Inflownomics of Raleigh, NC introduce a powerful information access network. ... experts in dangerous situations the Inflow IQ team can help people. Get ready ... & refreshing knowledge systems that enhance life. , Authentically enjoy 500 ...
    (Date:3/23/2017)... ... , ... The American Board of Quality Assurance and Utilization Review Physicians (ABQAURP) ... Health Care Quality and Management and Patient Safety. , It is with appreciation and ... also to the Health Care Quality and Patient Safety movements. Diplomates and Members lead ...
    Breaking Medicine News(10 mins):